Viragen News (AMEX:VRA)
| Latest Viragen News Headlines | | Date | Time | Source | | | 01/04/2007 | 5:03PM | PRNUS | Dawson James Securities Discusses 2007 Outlook for Biopure and Viragen
BOCA RATON, Fla., Jan. 4 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, discussed the outlook for Biopure Corp. (NASDAQ:BPUR) and Viragen, Inc. (AMEX:VRA) for 2007.
The interview with Stephen M. Dunn, Director of Research at Dawson James... More...>> |
| 07/31/2006 | 12:16PM | PRNUS | Viragen Files Preliminary Prospectus for Secondary Stock Offering
PLANTATION, Fla., July 31 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a secondary offering of Units, each Unit consisting of one share of common stock and one common stock purchase... More...>> |
| 07/28/2006 | 9:40AM | PRNUS | Viragen International Completes $1.8 Million Private Placement Financing
PLANTATION, Fla., July 28 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and its majority-owned subsidiary Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) today announced that Viragen International, Inc. has completed a private placement Unit offering to accredited investors providing gross proceeds... More...>> |
| 06/20/2006 | 9:56AM | PRNUS | Multiferon(R) Article Published in Leading Cancer Journal; Reports Significant Malignant Melanoma Survival Results
PLANTATION, Fla., June 20 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) , today announced that Acta Oncologica, a leading European journal in clinical oncology, has published an article profiling the use of Multiferon(R... More...>> |
| 05/31/2006 | 10:19AM | PRNUS | Viragen Reports Continued U.S. Army Studies of Multiferon(R); Research Marks Next Step Toward Determining Biodefense Potential
PLANTATION, Fla., May 31 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) , today reported that the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has agreed to commence with a new series of in... More...>> |
| 05/22/2006 | 12:54PM | PRNUS | Viragen to Highlight Multiferon(R) Treatment Advantages at Melanoma Conference
More...>> |
| 05/09/2006 | 10:20AM | PRNUS | Viragen Announces Research Collaboration With Prominent Biodefense Consultant to U.S.
Studies to Focus on Multiferon(R) as Broad-Acting Anti-Viral Agent Against Biowarfare Threats
PLANTATION, Fla., May 9 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company has entered into a research collaboration agreement with AFG BioSolutions, Inc., a prominent biodefense consultant... More...>> |
| 03/27/2006 | 10:41AM | PRNUS | Multiferon(R) Melanoma Article Accepted for Publication in Leading Cancer Journal
PLANTATION, Fla., March 27 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) , today announced that Acta Oncologica, a leading journal in clinical oncology, has accepted to publish an article profiling Multiferon(R) (multi-subtype... More...>> |
| 03/21/2006 | 5:19PM | PRNUS | Viragen Completes $5.2 Million Financing
PLANTATION, Fla., March 21 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced the completion of a private placement Unit offering to institutional and accredited investors providing gross proceeds of approximately $5.2 million. After fees and expenses, the Company received approximately $4.7 million... More...>> |
| 03/13/2006 | 6:05PM | PRNUS | Viragen Announces Financing Strategy
- $5 Million Bridge Round Announced - $20 Million Secondary Offering Planned
PLANTATION, Fla., March 13 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company has received approximately $4.1 million in gross proceeds from a private placement Unit offering to institutional and accredited... More...>> |
| 03/03/2006 | 4:30PM | PRNUS | Viragen Reports on Amex Compliance Plan
PLANTATION, Fla., March 3 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today provided an update related to the Company's plans to return to compliance with the American Stock Exchange's (Amex) continued listing requirements.
Viragen's common stock continues to trade on the Amex under a conditional trading extension... More...>> |
| 02/28/2006 | 9:50AM | PRNUS | Viragen to Present Multiferon(R) European Strategy at BioSquare 2006
PLANTATION, Fla., Feb. 28 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company is scheduled to make a presentation at BioSquare 2006, a premier European biotechnology partnering conference, to be held in Geneva, Switzerland during March 8-10.
Presentation details are as follows:... More...>> |
| 02/07/2006 | 9:15AM | PRNUS | Viragen Reports on Multiferon(R) Anti-Viral Studies with U.S. Army Researchers
PLANTATION, Fla., Feb. 7 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and its majority-owned subsidiary, Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) , today reported on the progression of anti-viral studies using Multiferon(R) (multi-subtype, natural human alpha interferon) being conducted by... More...>> |
| 01/19/2006 | 10:39AM | PRNUS | Viragen Announces Investment Banking Agreement With Janney Montgomery Scott
PLANTATION, Fla., Jan. 19 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company has entered into an investment banking agreement, appointing Janney Montgomery Scott LLC ("Janney") as its financial advisor. Janney will act on Viragen's behalf to evaluate strategic alternatives, including... More...>> |
| 01/18/2006 | 11:00AM | PRNUS | Viragen Reports Avian Transgenic Breakthrough: OVA(TM) System Expresses Interferon-Beta
PLANTATION, Fla., Jan. 18 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company's scientists, along with its collaborators at the Roslin Institute and Oxford BioMedica plc, have successfully achieved expression of significant quantities of the human protein, interferon beta-1a, in the whites... More...>> |
| 12/20/2005 | 1:57PM | PRNUS | Viragen Reports Annual Meeting Voting Results
PLANTATION, Fla., Dec. 20 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today reported voting results from its 2005 Annual Meeting of Stockholders held on December 15th in Plantation, Florida.
Stockholders approved all proxy voting items including:
1) The reelection of Dr. Randolph A. Pohlman and the election... More...>> |
| 12/15/2005 | 7:32AM | PRNUS | Viragen Holds Annual Stockholder Meeting: CEO Issues Progress Report
PLANTATION, Fla., Dec. 15 /PRNewswire-FirstCall/ -- The following is a letter from Charles A. Rice, President and CEO of Viragen, Inc. (AMEX:VRA). In addition to these comments, stockholders and potential investors are referred to: the Company's SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports);... More...>> |
| 12/06/2005 | 10:54AM | PRNUS | Viragen Announces Asian Expansion With South Korean Multiferon(R) Marketing Agreement
PLANTATION, Fla., Dec. 6 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that it has entered into a license agreement with Kuhnil Pharm Co. Ltd., headquartered in Seoul, to distribute Multiferon(R) (multi-subtype, natural human alpha interferon) in South Korea. While financial terms were not disclosed... More...>> |
| 11/21/2005 | 6:00AM | PRNUS | Viragen Comments on Avian Flu Results
PLANTATION, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Representatives from Viragen, Inc. (AMEX:VRA) and Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) provided comments related to a recent announcement reporting positive preliminary in vitro results from studies on Multiferon(R) (multi-subtype, human natural... More...>> |
| 11/18/2005 | 2:23PM | PRNUS | Viragen Reports Results from Preliminary Avian Flu Studies
Initial In Vitro Results Show Multiferon(R) to Be Effective Against Virus; Further Studies Needed
PLANTATION, Fla., Nov. 18 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) and Viragen International, Inc. (OTC:VGNI) (BULLETIN BOARD: VGNI) today announced that preliminary in vitro studies conducted by a U.S. research... More...>> |
|
|
|